Supervised Exercise and Revascularization for Intermittent Claudication

The combination of optimal medical treatment plus angioplasty plus supervised exercise seems to be the first line of treatment for patients with intermittent claudication, in terms of maximum walking distance and best quality of life. This combination requires a multidisciplinary team for the best possible results.

Continuar con la actividad física luego de un IAM reduce la mortalidad

The aim of this study was to conduct a meta-analysis comparing all therapeutic strategies for intermittent claudication, including optimal medical treatment, peripheral angioplasty, supervised exercise therapy, and their corresponding combinations, in order to determine the best treatment for intermittent claudication.

Intermittent claudication is a common problem that limits physical activity, decreases quality of life, and is associated with more cardiovascular events. There are previous meta-analyses, but none tested the impact of strategy combinations.

This study included data from 37 randomized studies, reaching almost 3000 patients with intermittent claudication (mean age was 68 years; 54.5% of patients were men). Comparisons were established between best medical treatment vs. supervised exercise vs. angioplasty vs. angioplasty plus supervised exercise.


Read also: Many Guidelines, Much Confusion. Blood Pressure Targets in the Elderly.


Angioplasty plus supervised exercise outperformed all other possible treatment strategies and obtained the maximum walking distance gain, 290 meters (p < 0.001).

As regards quality of life, the combination of angioplasty and supervised exercise also outperformed all other strategies. This does not mean that optimal medical treatment should be overlooked, since it acts over the whole range of cardiovascular disease.

The best course of action is a combination of all three strategies: optimal medical treatment aimed at a long/medium-term reduction in events (all cardiovascular events), angioplasty so that the patient experiences an acute difference and is able to begin with a supervised exercise plan, and, finally, such plan for result optimization and maintenance over time.

Original Title: Supervised Exercise Therapy and Revascularization for Intermittent Claudication Network Meta-Analysis of Randomized Controlled Trials.

Reference: Athanasios Saratzis et al. J Am Coll Cardiol Intv 2019, Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...